News from Bayer
May 23, 2022
Not intended for U.S. and UK Media - Late-breaking data from exploratory post hoc analysis of prespecified pooled analysis FIDELITY presented at Heart Failure 2022 of the Heart Failure Association of the European Society of Cardiology (ESC)
New data support renal and cardiovascular benefits of Kerendia™ (finerenone) in patients with and without history of left ventricular hypertrophy and chronic kidney disease and type 2 diabetes
May 23, 2022
Not intended for U.S. and UK Media
Two large Xarelto™ studies support effectiveness of dual pathway inhibition in patients with coronary artery disease and/or peripheral artery disease
May 19, 2022
Not intended for U.S. and UK Media
Bayer to present key data across oncology portfolio showcasing significant advances in cancer care at 2022 ASCO Annual Meeting
Explore All Stories
Please enter a term to search